Loading
ZP
Zynerba Pharmaceuticals, Inc. Stock: price and insider trades · United States
Zynerba Pharmaceuticals, Inc.: what insiders have been doing
This page follows insider dealings at Zynerba Pharmaceuticals, Inc. as filed with SEC (Form 4), a company from the Healthcare & Pharma sector based in Radnor, United States. The group dates from 2014. Zynerba Pharmaceuticals, Inc. has had no insider filing for more than a year; the last one goes back to 11 October 2023.
These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
61
Thresholds
n/a
Buy Volume
n/a
n/a
Sell Volume
€51,420
5 ops. · all time
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2018FY ended December 2018 · cache
Income statement
RevenueUS$74k
Net income-US$30.2M-40739.3% margin
Last declaration on 11 October 2023
Declarations61 total
341,241 sharesCommon StockSEC:0001140361-23-047738:0
40,520 sharesCommon StockSEC:0001140361-23-047746:0
27,954 sharesCommon StockSEC:0001140361-23-047725:0
123,087 sharesCommon StockSEC:0001140361-23-047742:0
27,954 sharesCommon StockSEC:0001140361-23-047743:0
33,685 sharesCommon StockSEC:0001140361-23-047729:0
27,954 sharesCommon StockSEC:0001140361-23-047731:0
27,954 sharesCommon StockSEC:0001140361-23-047735:0
32,941 sharesCommon StockSEC:0001140361-23-047727:0
69,559 sharesCommon StockSEC:0001140361-23-047733:0
566,722 sharesCommon StockSEC:0001140361-23-047723:0
27,954 sharesCommon StockSEC:0001140361-23-047722:0
9,000 sharesCommon StockSEC:0001062993-23-018019:0
22,200 sharesCommon StockSEC:0001062993-23-018021:0
31,200 sharesCommon StockSEC:0001062993-23-018020:0
45,000 sharesCommon StockSEC:0001062993-23-018022:0
64,747 sharesCommon StockSEC:0001062993-23-018018:0
47,824 shares0Common StockSEC:0001062993-23-013668:0
47,824 shares0Common StockSEC:0001062993-23-013665:0
47,824 shares0Common StockSEC:0001062993-23-013666:0
47,824 shares0Common StockSEC:0001062993-23-013663:0
47,824 shares0Common StockSEC:0001062993-23-013664:0
47,824 shares0Common StockSEC:0001062993-23-013667:0
3,173 shares@ US$0.5418100.0% of flowCommon StockSEC:0001062993-23-004049:0
22,547 sharesCommon StockSEC:0000899243-23-004444:0
25 of 61 declarations
About Zynerba Pharmaceuticals, Inc.
Zynerba Pharmaceuticals, Inc. is a U.S.-based biopharmaceutical company best known to market participants as a development-stage specialty pharma name, historically associated with SEC filings and insider-transaction reporting. The company was incorporated in Delaware in 2007 as AllTranz, Inc. and later changed its name to Zynerba Pharmaceuticals, Inc. in 2014. Its headquarters are in the United States, and its shares were listed on the U.S. market, specifically NASDAQ, which places the company within the highly regulated American public-equity and biotech ecosystem. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1621443/000155837019010074/zyne-20190930x10q.htm?utm_source=openai))
Operationally, Zynerba has been a focused clinical-stage company rather than a diversified pharmaceutical platform. Its core thesis has centered on pharmaceutically produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. The company’s lead development efforts have historically targeted Fragile X syndrome (FXS) and 22q11.2 deletion syndrome, while earlier disclosures also referenced autism spectrum disorder and a group of rare epilepsies. In SEC disclosures, Zynerba described itself as prioritizing resources on FXS and 22q11.2, both of which have no approved products. That makes the company a classic high-risk, high-upside biotech story: concentrated pipeline, meaningful unmet medical need, but substantial clinical, regulatory, and financing risk. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1621443/000155837023004765/zyne-20221231x10k.htm?utm_source=openai))
Read moreShow less
A key element of Zynerba’s positioning has been its transdermal delivery approach. In theory, a skin-applied cannabinoid formulation can offer differentiated convenience, steadier exposure, and potentially better tolerability than some oral approaches. That said, the commercial moat depends entirely on proof of efficacy, safety, manufacturability, and regulatory approval—none of which is guaranteed in orphan neurology. Zynerba has also highlighted FDA orphan-drug designations and European Commission orphan status for cannabidiol in FXS and 22q11.2 deletion syndrome, along with FDA Fast Track designation for behavioral symptoms associated with FXS. These designations can be strategically valuable, but they do not substitute for successful late-stage data or eventual commercialization. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1621443/000155837023004765/zyne-20221231x10k.htm?utm_source=openai))
From a competitive standpoint, Zynerba operates in a narrow but crowded scientific race: rare neuropsychiatric and neurologic diseases attract biotech, academic, and pharmaceutical competitors pursuing gene therapy, small molecules, and other precision approaches. Zynerba’s differentiation has been the cannabinoid/transdermal angle, but investor attention has primarily been driven by binary clinical milestones, cash runway, and capital-market events rather than by revenue generation. Recent SEC materials continue to characterize the company as a clinical-stage specialty pharmaceutical enterprise, underscoring its dependence on development outcomes and financing capacity. For international investors, especially those in Europe analyzing U.S.-listed healthcare small caps, Zynerba exemplifies the risk profile of NASDAQ biotech: concentrated pipeline exposure, heavy regulatory dependence, and a value proposition tied to future data rather than current sales. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1621443/000110465923048382/tm2311178d2_ars.pdf?utm_source=openai))
